Shanghai Administration Imposes Hefty Fine on H&S Pharmaceutical for Substandard Drugs
The Shanghai Municipal Medical Products Administration has disclosed that Hengshan (H&S) Pharmaceutical is under scrutiny...
Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...
Regeneron Pharmaceuticals Acquires 2seventy Bio to Boost Cell Therapy Capabilities
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the acquisition of U.S. biotechnology company 2seventy Bio Inc....
Hunan Province Hospitals Commit to Implementing Nationally Negotiated Drugs in Policy Seminar
A policy seminar under the auspices of the Hunan Healthcare Security Administration bureau convened in...
Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion
Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...
Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...
Shanghai CureGene Pharmaceutical Secures USD 14 Million in Series B Financing to Advance Cardiovascular Treatments
Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of...
Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good...
Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center
Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...
Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program
Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS)...
Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...
Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry
The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi...
AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...
SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing
SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD...
Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing...
South Korean Duo GC Wellbeing and YooYoung Pharmaceutical Target Chinese Filler Market
South Korean health and functional food manufacturer GC Wellbeing and YooYoung Pharmaceutical have formed a...
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...
Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial
Bristol Myers Squibb (BMS; NYSE: BMY) this week announced preliminary Phase III data demonstrating that...